CA 125 is not intended as a screening test. CA 125 is affected by menstrual cycle, ectopic endometrial tissue.
The CA 125 level can provide prognostic information in the follow-up management of patients with ovarian carcinoma. The assay should be used as an adjunctive test in the management of ovarian cancer patients. CA 125 is not recommended as a cancer screening procedure to detect cancer in the general population.